Background {#S0001}
==========

Chronic obstructive pulmonary disease (COPD) is often a progressive disease, characterized by persistent respiratory symptoms and airflow limitation, causing significant morbidity and mortality worldwide.[@CIT0001] COPD is associated with an economic, societal and personal burden that is evident at all stages of disease,[@CIT0002]--[@CIT0006] and reflected by high rates of emergency department visits, hospitalizations and readmissions.[@CIT0007]--[@CIT0010] However, there is a direct relationship between COPD severity and the cost of care, which increases with disease progression.[@CIT0011],[@CIT0012]

Despite an increased awareness and focus on COPD, there remains widespread under-recognition and under-diagnosis of the disease.[@CIT0013]--[@CIT0015] A retrospective analysis of clinical data from 1990 to 2009 observed that opportunities for diagnosis were missed in 85% of 38,859 COPD patients in the 5 years preceding diagnosis.[@CIT0016] Although undiagnosed, these patients utilize health services to a similar degree as diagnosed patients, and contribute considerably to the health care burden of the disease.[@CIT0015] Many patients with chronic airflow limitation are conscious of symptoms for a number of years before seeking medical help[@CIT0017],[@CIT0018] and may misinterpret breathlessness, minor symptoms and low exercise tolerance as normal features of aging and as such do not seek medical help.[@CIT0019] However, initiating treatment early in the course of COPD is likely to slow disease progression and improve patient-related outcomes.[@CIT0017]

Therefore, it is widely recognized that it is beneficial for COPD patients to receive an early diagnosis.[@CIT0020],[@CIT0021] However, there are few studies directly comparing the effect of an early versus late COPD diagnosis on patient-related outcomes and health care resource utilization.[@CIT0022] In an analysis of ARCTIC, a large real-world study, we investigated how the timing of COPD diagnosis is associated with clinical and economic outcomes in Swedish patients with COPD. There is no widely accepted method for identifying individuals who are at risk for development of COPD. Therefore, in this manuscript, we have identified factors that are associated with airways diseases (named indicators), which are likely predictors of a later COPD diagnosis.

Methods {#S0002}
=======

Study design {#S0002-S2001}
------------

This was a real-world, retrospective, observational cohort study of patients with COPD managed in primary care in Sweden. The study obtained ethical approval from the local Ethical Regional Board in Uppsala, Sweden, in December 2014 (number: 2014--397) and was conducted in accordance with the principles of the Declaration of Helsinki.

Electronic medical record (EMR) data were collected from COPD patients at 52 primary care centers across Sweden between 2000 and 2014, using an established software system (Pygargus Customized eXtraction Program \[CXP\]). Data collection included: age and gender, prescriptions (according to the World Health Organization \[WHO\] Anatomic Therapeutic Chemical \[ATC\] codes), diagnoses (according to the International Classification of Disease codes \[ICD-9/ICD-10 codes\]), spirometry measurements, laboratory tests, health care professional (HCP) visits and referrals. The centers covered urban and rural sites of varying size across Sweden. EMR data were linked using unique individual pseudonymized identification (ID) numbers to national registry data sources (see supplementary material).

Study patients {#S0002-S2002}
--------------

Patients eligible for inclusion were aged ≥40 years who had received either a physician's diagnosis of COPD (ICD-10 code: J44) in primary care (EMR database), or a physician's diagnosis of asthma (ICD-10 code: J45/J46) in primary care that was later verified as COPD in the hospital setting (according to the National Patient Register).

Data from EMRs were examined for early recorded indicators that should attract the doctor's attention to a potential COPD diagnosis during the 5 years prior to date of diagnosis (index date). Such indicators were pneumonia (ICD10 code J10--J18), respiratory diseases other than pneumonia (ICD10 code J00--J99), prescription of oral steroids (ATC code H02AB), prescription of antibiotics for airway and lung infections (ATC codes J01AA, J01CA), prescriptions for respiratory disease targeted to relieve respiratory symptoms (ATC code R01--03 and R05--07) and lung function measurements (from spirometry database and lab module in EMR). Patients with ≤2 registered indicators during the last 5 years prior to COPD diagnosis were classified as having an early diagnosis (ED) and patients with ≥3 indicators (registered \>90 days prior to the COPD diagnosis) during the 5 years prior to COPD diagnosis were classified as having a late COPD diagnosis (LD). A lag of time of 90 days prior to the index date was applied to ensure that no patients were incorrectly assigned to the LD group.

Outcomes {#S0002-S2003}
--------

Outcomes were recorded in the 2-year period prior to, and following the index date. The annual rate of, and time to first exacerbation were recorded during the 2 years following index date. Exacerbations were defined as COPD-related hospitalizations (J44 in primary position or J44.0/J44.1 in secondary) and emergency visits (J44.0/J44.1 in outpatient hospital care), or collection of oral steroids (ATC H02AB), or antibiotics targeted at respiratory diseases (ARC J01AA/J01CA). Mortality risk was recorded as time to death and calculated from the index date. Comorbidities were defined through diagnosis codes in the primary or secondary care setting and by medications according to the national prescription register. Health care resource utilization (HCRU) 2 years prior to, and following the index date was assessed by: drug costs, outpatient/inpatient COPD-related or unrelated hospital visits and primary care visits.

Statistical analysis {#S0002-S2004}
--------------------

Patient demographics (corresponding to the 2-year period prior to index date) were reported descriptively and are stratified by diagnosis timing (early vs late). Exacerbation risk was analyzed using Cox regression with time to first exacerbation as the dependent variable and group (ED/LD) as a factor. Mortality risk was analyzed using Cox regression with time to death as dependent variable and group (ED vs LD) as a factor. Comorbidities were presented as the percentage of patients with each condition while frequencies of comorbidities were calculated relative to the index date. Overall comorbidity burden was assessed by the Charlson Comorbidity Index. Medication use was calculated as the percentage of patients with a prescription in the 2-year period prior to the index date. HCRU were calculated for each group and plotted graphically. Sensitivity analyses excluded patients with a comorbid asthma diagnosis at any time in the patient's disease history.

A sample size calculation conducted prior to the study indicated that 13,800 patients were required to detect a 4% difference between groups, with a power of 80% and a significance level of 5%. Results are presented as age-adjusted mean values (95% confidence interval \[CI\]) or hazard ratio (HR, \[95% CI\]). Missing EMR data for essential risk factors were reviewed thoroughly in the data management process (eg, clinical measures, laboratory test results). Missing values were addressed by exclusion of non-essential variables, imputation based on average measures across the follow-up time frame or use of proxy algorithms. All analyses were performed using SAS version 9.3 or newer (SAS Institute Inc., Cary, NC) statistics software.

Results {#S0003}
=======

Patient demographics {#S0003-S2001}
--------------------

A total of 12,697 patients with a diagnosis of COPD were identified as eligible for inclusion, of which 3,870 (30.5%) and 8,827 (69.5%) were classified as ED or LD, respectively ([Figure 1](#F0001){ref-type="fig"}). Mean ages were 68.7 and 69.5 years in ED and LD groups, respectively (*P*=0.0005). Patients in the ED group were more likely to be male than female (53% vs 47%); conversely, the proportion of females was higher compared with males (57% vs 43%) in the LD group. Baseline characteristics are presented in [Table 1](#T0005){ref-type="table"}.Table 1Patient demographics of the early versus late diagnosis populationsVariable^a^Early diagnosis\
(n=3,870)Late diagnosis\
(n=8,827)*p*-valueMean age (years)68.7269.470.0005Gender, n (%)\<0.0001 Female1,821 (47.05)5,074 (57.48) Male2,049 (52.95)3,753 (42.52)Comorbidities Number of Charlson Comorbidity groups (95% CI)1.48 (1.46--1.52)1.81 (1.79--1.83)\<0.0001 Charlson Comorbidity Index value (95% CI)1.58 (1.54--1.62)1.94 (1.91--1.97)\<0.0001Comorbidities by ICD-10 code % (95% CI) Asthma, J453.93 (2.76--5.04)22.01 (21.3--22.8)\<0.0001 Rhinitis, J30/J310.54 (0.14--0.92)2.02 (1.76--2.28)\<0.0001 Cardiovascular diseases, I00--I9940.31 (39.4--42.4)46.6 (45.4--47.4)\<0.0001 Ischemic heart diseases, I20--I2510.78 (9.99--12.0)12.41 (11.6--13.0)0.009 Hypertensive diseases, I1024.13 (23.1--25.8)29.68 (28.6--30.5)\<0.0001 Cerebrovascular diseases, I60--I694.88 (4.31--5.70)5.29 (4.78--5.70)0.3404 Diabetes type I, E101.86 (1.38--2.33)2.56 (2.24--2.88)0.0165 Diabetes type II, E11/E136.77 (5.94--7.75)10.13 (9.50--10.7)\<0.0001 Hyperlipidemia, E78.52.40 (1.88--2.93)3.07 (2.72--3.42)0.0381 Depression, F32/F334.81 (3.95--5.50)7.28 (6.81--7.84)\<0.0001 Anxiety, F40/F413.90 (3.10--4.46)5.39 (5.00--5.89)\<0.0001 Mild cognitive impairment, F06.70.34 (0.13--0.58)0.60 (0.44--0.74)0.0564 Osteoporosis, M80/M811.91 (1.48--2.51)3.22 (2.84--3.53)\<0.0001 Fractures, S26.82 (6.04--7.70)7.76 (7.19--8.29)0.0641 Lung cancer, C340.93 (0.59--1.28)1.35 (1.12--1.57)0.0484Medication use by ATC code,% (95% CI) Treatment of cardiac disease, C0113.13 (12.3--14.27)18.55 (17.6--19.2)\<0.0001 Antihypertensives, C020.83 (0.52--1.17)1.19 (0.97--1.40)0.0687 Beta-blocking agents, C0725.99 (24.9--27.8)33.70 (32.6--34.5)\<0.0001 Calcium channel blockers, C0815.87 (14.9--17.4)22.51 (21.6--23.2)\<0.0001 Agents acting on the renin-angiotensin system, C0924.86 (23.8--26.7)36.04 (34.9--36.8)\<0.0001 Lipid modifying agents, C1018.94 (17.8--20.4)26.46 (25.5--27.2)\<0.0001 Diabetes medication, A107.62 (6.68--8.68)13.15 (12.5--13.8)\<0.0001 Antidepressants, N06A16.77 (15.3--18.0)27.88 (27.0--28.8)\<0.0001 Central pain killers, N02BE/N02A/M01AE28.32 (26.9--30.0)50.38 (49.3--51.3)\<0.0001 Bisphosphonates, M05BA2.12 (1.55--2.86)5.66 (5.19--6.06)\<0.0001 Proton pump inhibitors, A0216.5 (15.1--17.9)34.6 (33.7--35.5)\<0.0001 Oral steroids, H02AB5.45 (4.15--6.67)29.43 (28.6--30.3)\<0.0001 Antibiotic for airways, J01AA/J01CA14.19 (12.6--15.5)46.55 (45.7--47.6)\<0.0001Health care utilization Hospital visits per year for any reason, n0.41 (0.37--0.45)0.56 (0.54--0.59)\<0.0001 Outpatient^b^ visits per year, n1.36 (1.21--1.47)2.24 (2.16--2.33)\<0.0001 Primary care contacts per year, n7.76 (7.22--8.41)13.3 (12.9--13.4)\<0.0001 Patients with primary care contacts,%78.4 (77.1--79.7)77.9 (77.0--78.7)0.4739 Patients with outpatient hospital visits,%57.2 (55.7--58.6)72.1 (71.1--73.1)\<0.0001 Patients with overnight stays,%33.0 (31.7--34.7)39.7 (38.6--40.6)\<0.0001[^1] Figure 1Study cohorts and criteria for early versus late COPD diagnosis. ^a^Indicator diagnosis codes; Pneumonia J10--J18; respiratory diseases J00--J99, excluding pneumonia; oral steroids H02AB; antibiotics for respiratory disease J01AA, J01CA; prescription for respiratory disease R01--R03, R05--R07; lung function measurements from spirometry database and laboratory module in EMR. Disposition of patients by COPD and concomitant asthma versus COPD only is based on diagnosis at any time during the patient's disease history.**Abbreviation:** EMR, electronic medical records.

Exacerbations {#S0003-S2002}
-------------

The annual exacerbation rate in the total population was 1.41 (95% CI: 1.35--1.47) in the ED group and 2.67 (95% CI: 2.60--2.74) in the LD group (HR 1.89, 95% CI: 1.83--1.96; *P*\<0.0001) measured 2 years after diagnosis. Time to first exacerbation also differed between the groups (HR 1.61, 95% CI: 1.54--1.69; *P*\<0.0001; [Figure 2A](#F0002){ref-type="fig"}, [Table S1](#ST0001)).Figure 2Risk of exacerbations and mortality by stage of diagnosis (early vs late). Risk of exacerbations (**A**) and mortality (**B**) in the total population and risk of exacerbations (**C**) and mortality (**D**) in patients excluding those with concomitant asthma, in the year following diagnosis.

In patients with COPD only (ie, after exclusion of patients with a concomitant asthma diagnosis), the annual exacerbation rates were 1.37 (95% CI: 1.31--1.44) and 2.53 (95% CI: 2.43--2.63) exacerbations/year in those with ED and LD, respectively, and the time to first exacerbation was shorter in patients with LD than in patients with ED (HR 1.64, 95% CI: 1.55--1.73; *P*\<0.0001: [Figure 2C](#F0002){ref-type="fig"}, [Table S2](#ST0002)). This higher exacerbation risk in the LD group also remained 2 years after index date in patients with only COPD (HR 1.59, 95% CI: 1.51--1.67; *P*\<0.0001).

Among patients with COPD and concomitant asthma, the annual exacerbation rate was 1.58 (95% CI: 1.43--1.74) in ED and 2.85 (95% CI: 2.74--2.96) in LD (HR 1.43, 95% CI: 1.31--1.56 between groups; *P*\<0.0001; [Table 2](#T0006){ref-type="table"}). However, among patients with ED, the time to first exacerbation was longer in patients with COPD only compared with those with concomitant asthma (HR 0.89, 95% CI: 0.81--0.97; *P*\<0.05) whereas patients with only COPD and LD had an increased risk of exacerbations compared with ED patients with concomitant asthma (HR 1.41, 95% CI: 1.30--1.54, *P*\<0.0001; [Table 2](#T0006){ref-type="table"}).Table 2Influence of asthma on time to first exacerbation and mortality, early versus late COPD diagnosisOutcomeAll patients\
late diagnosis\
(n=8,827)Late diagnosis concomitant asthma\
(n=3,868)COPD-onlyEarly diagnosis\
(n=3,222)Late diagnosis\
(n=4,959)**Column heading versus early diagnosis with concomitant asthma (n=648)Exacerbation**1.42 (1.31--1.55)^a^1.43 (1.31--1.56)^a^0.89 (0.81--0.97)^b^1.41 (1.30--1.54)^a^**Mortality**1.41 (1.11--1.80)^b^1.42 (1.12--1.81)^b^1.71 (1.34--2.17)^a^1.82 (1.44--2.31)^a^[^2]

Mortality {#S0003-S2003}
---------

The risk of mortality was similar between the ED and LD groups overall (HR 1.04, 95% CI: 0.98--1.11; *P*=0.1838; [Figure 2B](#F0002){ref-type="fig"}, [Table S1](#ST0001)). However, after exclusion of patients with a concurrent asthma diagnosis, mortality was higher among patients in the LD group compared with those in the ED group (HR 1.10, 95% CI: 1.02--1.18; *P*=0.0095: [Figure 2D](#F0002){ref-type="fig"}, [Table S2](#ST0002)). Further, compared with ED patients with a comorbid asthma diagnosis, the risk of mortality was significantly higher among patients with COPD alone with both ED (HR 1.71, 95% CI: 1.34--2.17; *P*\<0.0001) and LD (HR 1.82, 95% CI: 1.44--2.31; *P*\<0.0001; [Table 2](#T0006){ref-type="table"}).

Comorbidities and use of medicines {#S0003-S2004}
----------------------------------

During the 2 years prior to diagnosis, patients in the LD group had a higher prevalence of comorbidities than those in the ED group. The Charlson Comorbidity Index (1.94 vs 1.59; *P*\<0.0001) and the rates of cardiovascular disease, hypertension, type II diabetes, hyperlipidemia, depression, anxiety and osteoporosis were higher in the LD than in the ED group ([Table 1](#T0005){ref-type="table"}).

Overall, 4,515 patients (35.6%) had also received an asthma diagnosis at any time point in their disease history; 648 (16.7%) patients in the ED group and 3,867 (43.8%) patients in the LD group. Of these 4,515 patients, the asthma diagnosis was received 0--2 years prior to index date in 152 (3.9%) patients in the ED group and 1,942 (22.0%) in the LD group (*P*\<0.0001). Corresponding figures for the asthma diagnosis made more than 2 years prior to index date were 62 (1.6%) patients in the ED group and 1,040 (11.8%) patients in the LD group. This implies that 5.5% of the patients in the ED group and 33.8% of the patients in the LD group had asthma diagnosed before they received their COPD diagnosis. Asthma was diagnosed after index date in 434 (11.3%) and 885 (10.0%) patients in the ED and LD groups, respectively.

Compared with the ED group, significantly higher percentages of patients in the LD group used medications such as beta-blockers, calcium-channel blockers, renin-angiotensin system modifiers, diuretics, lipid-modifying agents, diabetes medications, antidepressants and central pain-killers (*P*\<0.0001 for all; [Table 1](#T0005){ref-type="table"}). Furthermore, a significantly higher percentage of LD used oral steroids and antibiotics targeting respiratory infections compared with ED (*P*\<0.0001 for both; [Table 1](#T0005){ref-type="table"}).

Health care resource utilization {#S0003-S2005}
--------------------------------

During the 2 years prior to index date, patients in the LD group had a significantly higher number of primary care visits than patients in the ED group ([Table 1](#T0005){ref-type="table"}). In the 2 years post-diagnosis, the cost per patient including drug costs and primary and secondary care contacts was €22,526 and €19,481 in the LD and ED groups, respectively. In a time trend analysis, costs were consistently higher for LD versus ED, with differences achieving significance at four out of eight time points measured ([Figure 3](#F0003){ref-type="fig"}, [Table S3](#ST0003)). These differences were driven largely by costs associated with respiratory drugs and COPD-related hospital nights ([Table 3](#T0007){ref-type="table"}, [Figure 4](#F0004){ref-type="fig"}, [Table S4](#ST0004)).Table 3Direct health care costs and utilization in patients with early versus late COPD diagnosisVariable^a^Early diagnosis\
(N=3,870)Late diagnosis\
(N=8,827)*p*-valueCost per patient, Euro (95% CI) Total for respiratory drugs (R03)386.5 (353.7--419.4)900.1 (878.3--921.8)\<0.0001 Public cost314.0 (283.9--344.1)782.1 (762.1--802)\<0.0001 Individual patient cost72.6 (68.4--76.8)118.0 (115.3--120.8)\<0.0001 Total drug cost per patient460.8 (396.6--524.9)716.6 (674.2--759.1)\<0.0001 Public cost373.2 (310.4--436.0)595.3 (553.7--636.8)\<0.0001 Individual patient cost87.6 (80.0--95.3)121.4 (116.4--126.5)\<0.0001Utilization per patient per year, n (95% CI) Nights at hospital (COPD-related; J45)0.16 (0.03--0.38)1.17 (1.02--1.30)\<0.0001 Nights at hospital (non-COPD)11.65 (11.04--12.55)11.58 (11.01--12.02)0.5487 Hospitalization events (COPD-related; J44)0.03 (0.01--0.05)0.17 (0.16--0.18)\<0.0001 Hospitalization events (non-COPD)1.68 (1.59--1.78)1.79 (1.72--1.85)0.0933 Out hospital visits^b^ (COPD-related; J45)0.04 (0.02--0.06)0.15 (0.14--0.16)\<0.0001 Out hospital visits^b^ (non-COPD)3.76 (3.44--4.02)4.74 (4.56--4.94)\<0.0001 Primary care contact with physician13.06 (12.41--13.73)15.77 (15.33--16.21)\<0.0001 Primary care contact with persons other than physician9.20 (8.42--9.98)12.48 (11.96--13.00)\<0.0001 Number of referrals0.99 (0.91--1.06)1.22 (1.17--1.28)\<0.0001[^3] Figure 3Time trend in direct costs (Euro/year) according to the stage of diagnosis (early vs late). In the year 2007, 2010, 2012 and 2013, total yearly costs were significantly higher for late diagnosis versus early diagnosis.Figure 4Direct costs during the 2 years after COPD diagnosis by early vs late diagnosis. Costs were calculated from Swedish Krona based on exchange rates in 2013.**Abbreviations:** hospital nights, number of nights where the patient has been at the hospital; hospital visit, outpatient care where the patient did not stay overnight at the hospital.

There were no significant differences in the annual number of primary care contacts and hospital visits between ED with concomitant asthma and ED with COPD only during 2 years preceding diagnosis ([Table 4](#T0008){ref-type="table"}). However, LD patients with concomitant asthma had a significantly higher number of primary care visits than LD patients with COPD only and a significantly higher percentage of LD patients with concomitant asthma had more primary care contacts and overnight stays than LD patients with COPD only ([Table 4](#T0008){ref-type="table"}).Table 4Health care resource utilization stratified by a concomitant diagnosis of asthma, early versus late diagnosisVariable^a^Early diagnosisLate diagnosisConcomitant asthma\
(N=648)COPD only\
(N=3,222)*p*-value^b^Concomitant asthma\
(N=3,868)COPD\
only\
(N=4,959)*p*-value^b^Mean age, years66.2769.21\<0.000168.5170.22\<0.001Number of hospital visits per year for any reason0.350.420.09120.600.530.0225Number of out hospital visits per year^c^1.111.410.01682.202.270.4461Number of primary care contacts per year7.447.820.479015.9711.16\<0.0001Patients with overnight stays,%28.7033.800.011841.1138.660.0196Patients with primary care contact,%79.4878.210.475882.0174.61\<0.0001[^4]

Discussion {#S0004}
==========

The present study shows that receiving an early COPD diagnosis is associated with significant benefits compared with receiving a diagnosis later in the course of the disease. Compared with a LD, early COPD diagnosis was associated with fewer exacerbations, fewer comorbidities and lower health care utilization in the 2 years following index date. Based on the present data, receiving a COPD diagnosis soon after having visited a doctor due to airway symptoms is associated with better clinical and economic outcomes than receiving the COPD diagnosis later during the course of the disease despite earlier presence of indicators of airway disease.

It is unclear why the majority of patients in the present study received an LD of COPD. Patients may delay seeking treatment for symptoms in some instances; however, we found that indicators suggestive of chronic airway disease had been present and registered by a medical professional \>90 days prior to the receipt of a COPD diagnosis in all LD patients. It is likely that a delay in diagnosis in the present study was due to initial misdiagnosis by HCPs. Additionally, time-pressured doctor--patient consultations, a low general awareness of COPD and insufficient local routines for COPD care may have contributed.[@CIT0023] It is also possible that patient comorbidities require more attention from a treating physician, thereby moving the focus away from COPD symptoms, resulting in a delayed COPD diagnosis.

Patients with chronic airflow obstruction frequently have features of both asthma and COPD, a condition sometimes called asthma-COPD overlap, and often have both an asthma and a COPD diagnosis. Patients with asthma-COPD overlap, particularly those with late-onset asthma, seem to have more frequent exacerbations and poor prognosis compared with patients who have only asthma or COPD.[@CIT0024],[@CIT0025] In the present study, asthma was much more common in the LD group than in the ED group. While similar proportions of patients received an asthma diagnosis after index date in the ED and LD groups, six times more patients in the LD group than in the ED group received an asthma diagnosis prior to index date.

This may have influenced the results in two ways. Firstly, in patients who already had an asthma diagnosis, the responsible doctor may not have considered the possibility of COPD, a diagnosis that was therefore missed. Secondly, as some patients had asthma before index date, this may have increased the number of registered "COPD indicators" (prescription due to respiratory symptom, lung function assessment and to some extent oral steroid treatment), measures which may have been taken due to asthma and therefore not regarded as direct predictors of COPD. On the other hand, all patients included in our analysis eventually received a COPD diagnosis, most of them within 2 years after the asthma diagnosis. This suggests that the indicators should also have been considered as predictive indicators of COPD. These findings indicate that there may be a need for increased awareness of the co-existence between asthma and COPD and that COPD should be considered in adult patients who are under treatment for asthma at primary health care centers.

It could be argued that pre-existing asthma may increase the risk of overestimating the occurrence of LD. However, this did not influence our main results as the main outcomes were similar after also excluding patients with asthma from the analyses. Further, data support the beneficial effects of early treatment in COPD.[@CIT0017] It is therefore imperative that primary care physicians are aware of the clinical indicators associated with COPD, in order to facilitate the early identification and treatment of patients with the disease. Even patients with mild or moderate COPD can suffer from substantial limitations and physical impairment which worsen with disease progression,[@CIT0022] and the rate of forced expiratory volume in 1 second decline is faster in patients with mild and moderate COPD than in those with very severe disease.[@CIT0026],[@CIT0027] Furthermore, the early treatment of acute exacerbations in COPD is associated with a faster recovery and the prevention of future exacerbations versus a delay in intervention, while failure to report acute exacerbations is associated with impaired health-related quality of life and increased hospitalization.[@CIT0028]

Patients with ED with concomitant asthma were at higher risk and experienced a higher annual rate of exacerbations than patients with COPD only, suggesting that a concomitant asthma diagnosis increases the risk of exacerbations even in the mild stages of COPD. A strong association between asthma and chronic bronchitis in "middle-aged" (early to mid-forties) adults has previously been demonstrated.[@CIT0029] Furthermore, as chronic bronchitis is associated with increased number and severity of exacerbations,[@CIT0030] it is tempting to speculate that this could have contributed to the increased risk of exacerbation observed in patients with concomitant asthma compared with COPD only.

Although there was no overall difference in mortality between ED and LD, mortality was higher in LD than in ED in patients with COPD only, ie, after exclusion of patients with a concomitant asthma diagnosis. The presence of asthma appears to "dilute" the negative effect of late COPD diagnosis on mortality, a finding that is supported by the significant differences in mortality found when results were stratified according to asthma diagnosis. In both ED and LD, patients with concomitant asthma had a significantly lower rate of mortality than patients without concomitant asthma. Patients with features of both asthma and COPD (asthma--COPD overlap) are known to experience more frequent exacerbations, a poorer quality of life, a more rapid decline in lung function and a higher rate of mortality than those with either asthma or COPD alone.[@CIT0024],[@CIT0031] It is likely that ED patients diagnosed with concomitant asthma had a mild or moderate COPD component to disease; however, some patients may have suffered from severe asthma. A less-severe COPD component in patients with concomitant asthma compared with COPD only patients could provide one explanation for the observed differences in mortality.

We found that LD patients suffered more frequently from comorbidities such as cardiovascular disease, depression, osteoporosis and diabetes than ED patients. It is well known that there is an association between COPD and a number of comorbidities, which may have an impact on the course of the disease, and that COPD can adversely affect the outcome of other disorders. For example, there is a greater rate of morbidity and mortality in hospitalized patients undergoing cardiac procedures when COPD is present compared with when it is absent.[@CIT0032] The presence of other diseases could have contributed to an LD of COPD as physicians may have given greater priority to the treatment of other morbidities, overlooking or misdiagnosing the respiratory symptoms indicative of COPD. For example, symptoms of breathlessness in patients with heart failure or lung cancer could have been overlooked, while fatigue and reduced physical activity could have been disregarded in patients with depression.[@CIT0033]

We also observed that health care utilization and total drug cost were significantly higher in LD patients compared with ED. This finding is likely to relate to the higher prevalence of comorbidities in LD patients, in line with previous studies which have shown annual costs to be higher in COPD patients with comorbidities than in those without.[@CIT0034] In LD patients, the presence of concomitant asthma led to a significantly higher rate of primary care contacts and percentage of patients with overnight stays, consistent with evidence that patients with both asthma and COPD features experience poorer outcomes than those with either asthma or COPD alone,[@CIT0024],[@CIT0031] and will utilize a greater proportion of health care resources.

This study has a number of strengths. The large sample size of COPD patients from a primary care setting and the robust outcomes of this study provide data that are highly representative of the general population.[@CIT0035]--[@CIT0037] Furthermore, the cohort study design allows for the investigation of a temporal relationship between outcome variables which otherwise would not have been possible to investigate in a cross-sectional study.[@CIT0038] Although there is no accepted method by which to define an ED and a LD, we believe that identifying indicators of respiratory symptoms, or disease, in patients who later received a COPD diagnosis was a credible approach to the identification of undiagnosed COPD. Furthermore, introducing a 90-day lag time prior to the date of diagnosis allowed an acceptable period of time for physician investigation, and ensured that no patients were incorrectly assigned to the LD group.

A potential limitation to this study is the retrospective study design, which introduces the potential for bias and confounding. As only Swedish patients were enrolled, this may limit the generalizability of these results to a more diverse group of patients and to different health care systems.[@CIT0039] However, we believe our findings have important clinical implications. If an earlier COPD diagnosis is associated with improved outcomes and reductions in the overall costs associated with the disease, primary care physicians have a responsibility to detect the early signs of COPD, perform relevant tests in a timely manner, make an accurate diagnosis and treat patients appropriately.

Clinical implications and conclusion {#S0005}
====================================

In conclusion, early COPD diagnosis is associated with a lower risk of exacerbations, fewer comorbidities and lower costs. Additionally, there may be mortality benefits of accurately differentiating asthma from COPD. This study indicates that an earlier diagnosis may lead to improved clinical outcomes while concomitantly reducing the economic burden of COPD. The study also indicates that a pre-existing asthma diagnosis may increase the risk of missing a COPD diagnosis.
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Methods {#S0011-S2001}
-------

### National registry data sources {#S0011-S2001-S3001}

Electronic medical record (EMR) data were linked using unique individual pseudonymized identification (ID) numbers to national registry data sources.

These included: Longitudinal Integration Database for Health Insurance and Labor Market Studies (LISA), which contains socio-demographic data, including: educational level, marital status and family situation, occupational status, retirement, economic compensation and social benefitsNational Patient Register, which contains data relating to diagnosis (International Classification of Disease \[ICD\]-10 code and associated position): surgery, gender, age, region, hospital visits, specialty visits, hospital admissions and discharges, and medical procedures and surgeries performed in inpatient and outpatient specialist settingsNational Prescription Register, which contains the full details of all dispensed medications (Anatomic Therapeutic Chemical \[ATC\] codes) from both primary and secondary care including: brand name, prescription date, dose, strength, pack size, specialty of the prescriber and costs associated with the drug prescriptionCause of Death Register, which holds information relating to sex, date of death and underlying cause of death.

Results {#S0011-S2002}
-------

Table S1Risk of exacerbations and mortality according to the stage of diagnosis (early versus late): total populationYears since index dateRisk of exacerbation, percentage of patients without event (95% CI)Risk of mortality, percentage of patients without event (95% CI)Early diagnosisLate diagnosisEarly diagnosisLate diagnosis2.535.0 (33.5--36.5)18.1 (17.3--18.9)83.7 (82.5--84.9)82.6 (81.8--83.5)5.022.7 (21.3--24.1)10.7 (10.0--11.4)71.5 (69.9--73.0)69.6 (68.5--70.7)7.516.2 (14.9--17.5)7.4 (6.7--8.1)59.4 (57.6--61.2)58.9 (57.6--60.3)10.012.8 (11.6--14.1)5.8 (5.2--6.5)48.8 (46.8--50.8)48.1 (46.4--49.7)12.511.4 (10.2--12.7)5.1 (4.4--5.8)38.7 (36.5--41.0)39.1 (37.1--41.0)15.010.5 (9.2--11.9)4.7 (4.0--5.5)30.8 (28.0--33.6)30.8 (28.2--33.5)17.510.0 (8.5--11.6)4.7 (4.0--5.5)24.4 (20.2--28.9)24.8 (19.7--30.1)[^5] Table S2Risk of exacerbations and mortality according to the stage of diagnosis (early versus late): patients excluding those with concomitant asthma (COPD-only population)Years since index dateRisk of exacerbation, percentage of patients without event (95% CI)Risk of mortality, percentage of patients without event (95% CI)Early diagnosisLate diagnosisEarly diagnosisLate diagnosis2.535.9 (34.3--37.6)19.0 (17.9--20.2)81.6 (80.1--82.9)80.2 (79.0--81.4)5.024.0 (22.4--25.5)12.0 (11.0--13.1)68.6 (66.9--70.3)65.3 (63.7--66.9)7.517.4 (15.9--18.9)8.3 (7.3--9.4)56.1 (54.0--58.1)53.9 (51.9--55.8)10.014.2 (12.8-- 15.6)6.3 (5.3--7.4)45.6 (43.3--47.8)42.9 (40.5--45.3)12.512.8 (11.4--14.3)5.4 (4.4--6.6)36.3 (33.7--38.9)34.5 (31.6--37.5)15.011.7 (10.1--13.3)4.8 (3.6--6.2)29.7 (26.4--33.1)24.3 (20.0--28.9)17.511.7 (10.1--13.3)4.8 (3.6--6.2)24.7 (19.6--30.1)20.6 (13.5--28.8)[^6] Table S3Time trend in direct overall costs (Euro/year) according to the stage of diagnosis (early versus late)YearTotal,\
€/yearEarly diagnosis,\
€/yearLate diagnosis,\
€/year20069,776.48,474.210,83520079,450.47,890.310,65620089,202.58,515.49,692.2200910,7159,346.911,611201010,6268,825.211,673201111,1269,687.311,871201210,9479,138.511,816201310,8598,994.911,677 Table S4Health care resource utilization direct costs over 2 years after index date according to stage of diagnosis (late vs early)Early diagnosis, €Late diagnosis, €Drugs, respiratory (R03)386.5900.1Drugs, other460.8716.6Hospital nights, COPD (J45)191.61,397.48Hospital nights, not COPD13,944.8913,865.85Hospital visits, COPD (J45)15.056.25Hospital visits, not COPD1,410.01,777.5Primary care contacts, physician2,386.722,881.97Primary care contacts, not physician685.4929.76[^7][^8]

[^1]: **Notes:** ^a^Variables quoted for 2 years prior to COPD diagnosis (index) date unless otherwise stated; all variables except age itself are calculated with age as a covariate. ^b^Outpatient visit: a visit where the patient does not stay overnight at the hospital.

    **Abbreviations:** ATC, anatomical therapeutic chemical; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICD-10, international classification of disease code.

[^2]: **Notes:** ^a^*P*\<0.0001; ^b^*P*\<0.05. Data are for the 2 years following COPD diagnosis, presented as HR (95% confidence interval), patients with early versus late diagnosis. Concomitant asthma includes patients with a comorbid asthma diagnosis.

    **Abbreviations:** COPD, chronic obstructive pulmonary disease; HR, hazard ratio.

[^3]: **Notes:** ^a^All variables are calculated with age as a covariate. Data are for the 2 years following COPD diagnosis. ^b^Out hospital visit: a visit where the patient does not stay overnight at the hospital. R03 indicates the ATC prescription code for respiratory disease. Exchange rates in 2013, 8 Swedish Krona= 1 Euro.

[^4]: **Notes:** ^a^All variables except age itself are calculated with age as a covariate. Data are for the 2 years prior to COPD diagnosis. ^b^*p*-values indicate comparisons between patients with a concomitant diagnosis of asthma and those with COPD-only. ^c^Out hospital visit: a visit where the patient does not stay overnight at the hospital.

[^5]: **Abbreviation:** CI, confidence interval.

[^6]: **Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease.

[^7]: **Notes:** Costs were based on unit costs for hospital nights (9,580 SEK), hospital visits (3,000 SEK), primary care visits, physician (1,462 SEK) and primary care visits, nurse (596 SEK) and converted to Euros based on exchange rates in 2013 (8/1).

[^8]: **Abbreviations:** COPD, chronic obstructive pulmonary disease; SEK, Swedish Krona; Hospital nights, number of nights where the patient has been at the hospital; hospital visit, outpatient care where the patient did not stay overnight at the hospital.
